Wei Li

机构：First Bethune Hospital of Jilin University, Jiangsu Province Hospital, Nanjing Medical University · ORCID：0000-0002-9961-6790

发表论文 31 篇 · 总被引 767 次 · h-index 15

代表论文

• Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 (2022 · Journal of Clinical Oncology · 被引 164)
• Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis (2018 · BMC Cancer · 被引 95)
• Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 (2022 · The Oncologist · 被引 53)
• Systemic immune inflammation index with all-cause and cause-specific mortality: a meta-analysis (2024 · Inflammation Research · 被引 38)
• MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma (2020 · Aging · 被引 36)
• <p>Potential Diagnostic Value Of Combining Inflammatory Cell Ratios With Carcinoembryonic Antigen For Colorectal Cancer</p> (2019 · Cancer Management and Research · 被引 31)